抗菌薬感受性試験市場：製品タイプ、試験法、用途、エンドユーザー別-2025-2030年世界予測

抗菌薬感受性試験市場は、2023年に38億1,000万米ドルと評価され、2024年には40億2,000万米ドル、CAGR 5.83%で成長し、2030年には56億7,000万米ドルに達すると予測されています。

抗菌薬感受性試験は、抗生物質耐性と闘い、治療戦略を洗練させるための世界の取り組みを支える、ヘルスケアおよび調査部門における不可欠な要として台頭してきました。薬剤耐性病原体の急増と感染症の進化が相まって、技術革新に拍車がかかり、利害関係者は検査における高度な手法を追求するようになりました。この複雑なエコシステムは、目覚ましい科学的ブレークスルー、自動化の統合、デジタルアナリティクスの導入を通じて変貌を続け、より正確でタイムリーな診断につながっています。

技術の進歩は、こうした検査の精度を高めるだけでなく、微生物の挙動をより包括的に理解することも可能にしました。迅速でスケーラブルなソリューションに対する需要の高まりは、新しい機器、試薬、革新的な検査サービスの採用に拍車をかけています。このダイナミックな環境は、自動化、データ駆動型プロセス、最先端手法の統合に重点が置かれていることを特徴としており、これらは総体として患者転帰の改善やより効果的な創薬プロセスの実現に寄与しています。

このセクターは、規制要件や品質基準を克服すると同時に、所要時間の短縮や検査プロトコルの自動化を約束する技術革新を受け入れています。研究者、臨床医、業界関係者は、これらの検査を改良し、臨床と研究の両方の場面で感染症対策の最前線に立ち続けられるよう、絶えず協力しています。本レポートは、抗菌薬感受性検査が現在の状況においてどのような位置づけにあるかを全体的に把握し、その重大な影響と今後待ち受ける変革的なシフトを理解するための舞台を提供します。

抗菌薬感受性試験市場の変革

近年、抗菌薬感受性試験の状況は大きく変化しています。新興感染症のプレッシャーと耐性病原体の複雑化によって加速されたこのセクターは、急速な技術的進歩と戦略的な市場再編成によって大きな変化を遂げました。自動化システム、高度な計算ツール、合理化されたワークフローの統合は、検査の手法を再定義し、時間の遅れを減らし、診断結果の精度を向上させました。

自動化されたプラットフォームとデジタル化された分析は、多くの臨床検査室や研究室で標準となり、従来の手作業から移行しています。この移行は、再現性、標準化、大量サンプルの処理能力を向上させた自動分析装置の機能強化が主な原因です。ハードウェアの革新とソフトウェアの統合の融合は、現在、抗菌薬耐性パターンをより高感度に検出するパラダイムシフトを推進しています。

さらに、この進化は機器の設計や手順のアプローチだけでなく、サービスプロバイダーの戦略的枠組みにも影響を与えています。包括的な分析検査やカスタムソリューションへの信頼が高まりつつあり、よりダイナミックで迅速な検査環境への道が開かれつつあります。このような変化が収束するにつれ、この部門はヒューマンエラーの減少、スループットの向上、特定の臨床課題に対するソリューションのカスタマイズ能力の強化から恩恵を受ける。その結果、現代の状況は適応的な性質によって定義され、抗菌薬感受性試験の熟練した専門家にとっても、新たな革新者にとっても刺激的な時代となっています。

市場力学を牽引する主要セグメンテーションインサイト

抗菌薬感受性試験市場は、さまざまな用途やエンドユーザーにわたる多様なニーズに対応する能力を高める複雑なセグメンテーション構造によって特徴付けられます。主要なセグメンテーション基準の1つは製品タイプに基づくもので、これにより市場がどのように機器、試薬・キット、サービスに分割されるかについての洞察が得られます。この大分類の中で、機器はさらに自動システムと手動機器に分けられ、自動システムは自動分析装置と自動プレートリーダーに区分されます。このように細かく分類することで、利害関係者はハイエンドの自動化ソリューションと従来型の手動ソリューションの両方の技術的進歩と採用率を注意深くモニターすることができます。

もう1つの重要なセグメンテーションは検査タイプに基づくもので、市場は抗菌薬、抗真菌薬、抗寄生虫薬、抗ウイルス薬の感受性検査で区別されます。このセグメンテーションは、さまざまな病原体プロファイルと治療ニーズに重点を置き、多様な臨床・研究要件に対応するものです。この分野は、検査手法に対する微妙なアプローチを必要とする新たな耐性パターンに対処するために、継続的に進化しています。

市場セグメンテーションでは市場力学をさらに細分化し、定性的手法と定量的手法に分類しています。寒天希釈法、自動AST法、ディスク拡散法、ジェノタイピング法などの定性法は、微生物耐性の有無に関する貴重な洞察を提供する一方、ブロスマクロ希釈法やEtest法などの定量法は、治療プロトコルを調整するために重要な感受性の正確な測定値を提供します。さらに、アプリケーションに基づくセグメンテーションでは、臨床診断、創薬研究開発、疫学に焦点を当て、これにより、個別の医療・研究分野における使用状況や需要の推移を専門的に分析することを容易にしています。

セグメンテーションの枠組みは、市場を学術・政府研究機関、病院・診断センター、製薬・バイオテクノロジー企業に分類するエンドユーザーの視点によってさらに強化されています。この層別化は、抗菌薬感受性試験ソリューションを利用する事業体の多様性を浮き彫りにするだけでなく、調達と技術採用を促進する様々な意思決定要因も指摘しています。全体として、これらのセグメンテーションの洞察は、多面的な市場構成要素および抗菌薬感受性試験技術の進歩に対するそれらの相対的な影響に関する包括的な視点を提供します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 医療上の意思決定における抗菌薬感受性試験の重要性
    • 感染症の予防と対策を目的とした政府の好ましい取り組み
  • 抑制要因
    • 抗菌薬感受性検査キットの高コストと熟練した専門家の不足
  • 機会
    • 新たなゲノム同定法の導入と抗菌薬感受性検査キットの発売
    • ナノ粒子ベースの抗菌薬感受性に関する進行中の調査
  • 課題
    • 製品リコールの発生と抗菌薬感受性試験商品化に関する厳しい規制
• 市場セグメンテーション分析
  • 製品タイプ：精度と効率性により抗菌薬感受性試験の需要が増加,
  • 試験の種類：侵襲性真菌感染症に対する意識の高まりにより、抗真菌薬感受性試験が大きく進歩しました。
  • 方法：検査精度を向上させた定性AST技術の開発
  • 応用：臨床診断、医薬品の発見と開発におけるASTの迅速かつ極限的な利用
  • エンドユーザー：病院や診断研究室でのASTの広範な使用
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社会
  • 技術的
  • 法律上
  • 環境

第6章 抗菌薬感受性試験市場：製品タイプ別

• 機器
  • 自動化システム
    • 自動分析装置
    • 自動プレートリーダー
  • 手動楽器
• 試薬とキット
  • 抗生物質感受性キット
  • 微生物同定キット
• サービス
  • 分析試験サービス
  • カスタムテストソリューション

第7章 抗菌薬感受性試験市場テストの種類別

• 抗菌薬感受性試験
• 抗真菌薬感受性試験
• 抗寄生虫薬感受性試験
• 抗ウイルス感受性試験

第8章 抗菌薬感受性試験市場：方法別

• 定性的な方法
  • 寒天希釈液
  • 自動Ast
  • ディスク拡散
  • 遺伝子型法
• 定量的手法
  • ブロスマクロ希釈
  • Eテスト法

第9章 抗菌薬感受性試験市場：用途別

• 臨床診断
• 医薬品の発見と開発
• 疫学

第10章 抗菌薬感受性試験市場：エンドユーザー別

• 学術機関および政府調査機関
• 病院と診断センター
• 製薬・バイオテクノロジー企業

第11章 南北アメリカの抗菌薬感受性試験市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の抗菌薬感受性試験市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの抗菌薬感受性試験市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析, 2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Accelerate Diagnostics, Inc.
• Alifax S.r.l.
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
• Biological Safety Solutions Ltd/Oy
• BioMerieux SA
• Bruker Corporation
• Creative Diagnostics
• Danaher Corporation
• Erba Lachema s.r.o.
• Eurofins Scientific SE
• F. Hoffmann-La Roche AG
• Himedia Laboratories Private Limited
• INTEGRA Biosciences AG
• Laboratorios Conda, S.A.
• Launch Diagnostics Limited
• Leading Biology, Inc.
• Liofilchem S.r.l.
• Mast Group Ltd.
• MP Biomedicals, LLC
• Pfizer Inc.
• Qiagen N.V.
• QuantaMatrix Inc.
• Resistell AG
• Synoptics Group
• Thermo Fisher Scientific Inc.
• Zhuhai DL Biotech Co., Ltd.

LIST OF FIGURES

• FIGURE 1. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET MULTI-CURRENCY
• FIGURE 2. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET MULTI-LANGUAGE
• FIGURE 3. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET RESEARCH PROCESS
• FIGURE 4. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2023 VS 2030
• FIGURE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 6. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET DYNAMICS
• TABLE 7. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED PLATE READERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MANUAL INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBIOTIC SUSCEPTIBILITY KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY MICROBIAL IDENTIFICATION KITS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANALYTICAL TESTING SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CUSTOM TESTING SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIBACTERIAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIFUNGAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIPARASITIC SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ANTIVIRAL SUSCEPTIBILITY TESTING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AGAR DILUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED AST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DISK DIFFUSION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY GENOTYPIC METHOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY BROTH MACRODILUTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ETEST METHOD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY CLINICAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 41. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 42. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY EPIDEMIOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 43. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 44. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 45. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 46. GLOBAL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 49. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 50. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 51. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 52. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 54. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 55. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 56. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 58. AMERICAS ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 59. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 60. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 61. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 62. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 63. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 64. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 65. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 66. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 67. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 68. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. ARGENTINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 70. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 71. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 72. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 73. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 74. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 75. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 76. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 77. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 78. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 79. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 80. BRAZIL ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 81. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 82. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 83. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 84. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 85. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 86. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 87. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 88. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 89. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 90. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 91. CANADA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 92. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 93. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 94. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 95. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 96. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 97. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 98. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 99. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 100. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 101. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. MEXICO ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 103. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 104. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 105. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 106. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 107. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 108. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 109. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 110. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 111. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 112. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 113. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 114. UNITED STATES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 115. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 116. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 117. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 118. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 119. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 120. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 121. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 122. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 123. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 124. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 125. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 126. ASIA-PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 127. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 128. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 129. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 130. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 131. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 132. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 133. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 134. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 135. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 136. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 137. AUSTRALIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 138. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 139. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 140. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 141. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 142. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 143. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 144. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 145. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 146. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 147. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. CHINA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 149. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 150. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 151. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 152. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 153. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 154. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 155. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 156. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 157. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 158. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 159. INDIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 160. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 161. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 162. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 163. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 164. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 165. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 166. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 167. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 168. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 169. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 170. INDONESIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 171. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 172. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 173. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 174. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 175. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 176. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 177. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 178. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 179. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 180. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. JAPAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 182. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 183. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 184. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 185. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 186. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 187. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 188. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 189. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 190. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 191. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 192. MALAYSIA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 193. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 194. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 195. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 196. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 197. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 198. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 199. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 200. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 201. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 202. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 203. PHILIPPINES ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 204. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 205. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 206. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 207. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 208. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 209. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 210. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 211. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 212. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 213. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 214. SINGAPORE ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 215. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 216. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 217. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 218. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 219. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 220. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 221. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 222. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 223. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 224. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 225. SOUTH KOREA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 226. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 227. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 228. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 229. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 230. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 231. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 232. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 233. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 234. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 235. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 236. TAIWAN ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 237. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 238. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 239. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 240. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 241. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 242. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 243. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 244. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 245. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 246. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. THAILAND ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 248. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 249. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 250. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 251. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 252. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 253. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 254. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 255. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 256. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 257. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 258. VIETNAM ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 259. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 260. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 261. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 262. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 263. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 264. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 265. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 266. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 267. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 268. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 269. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 270. EUROPE, MIDDLE EAST & AFRICA ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 271. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 272. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 273. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 274. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 275. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 276. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 277. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 278. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 279. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 280. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 281. DENMARK ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
• TABLE 282. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
• TABLE 283. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY INSTRUMENTS, 2018-2030 (USD MILLION)
• TABLE 284. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY AUTOMATED SYSTEMS, 2018-2030 (USD MILLION)
• TABLE 285. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY REAGENTS & KITS, 2018-2030 (USD MILLION)
• TABLE 286. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
• TABLE 287. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
• TABLE 288. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY METHOD, 2018-2030 (USD MILLION)
• TABLE 289. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUALITATIVE METHODS, 2018-2030 (USD MILLION)
• TABLE 290. EGYPT ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET SIZE, BY QUANTITATIVE METHODS, 2018-2030 (USD MILLION)

TABLE 2

The Antimicrobial Susceptibility Testing Market was valued at USD 3.81 billion in 2023 and is projected to grow to USD 4.02 billion in 2024, with a CAGR of 5.83%, reaching USD 5.67 billion by 2030.

Antimicrobial susceptibility testing has emerged as an essential cornerstone in the healthcare and research sectors, underpinning the global effort to combat antibiotic resistance and refine therapeutic strategies. The rapid escalation of drug-resistant pathogens coupled with an evolving landscape of infectious diseases has fueled innovation and motivated stakeholders to pursue advanced methodologies in testing. This complex ecosystem continues to transform through remarkable scientific breakthroughs, integration of automation, and the incorporation of digital analytics, leading to more accurate and timely diagnostics.

Technological progress has not only enhanced the precision of these tests, but also enabled a more comprehensive understanding of microbial behavior. The increased demand for expedited and scalable solutions has spurred adoption of novel instruments, reagents, and innovative testing services. This dynamic environment is characterized by a strong emphasis on automation, data-driven processes, and integration of cutting-edge methodologies that collectively contribute to improved patient outcomes and more effective drug discovery processes.

As the sector navigates regulatory requirements and quality standards, it simultaneously embraces innovations that promise reductions in turnaround time and automation in test protocols. Researchers, clinicians, and industry professionals are continually working together to refine these tests, ensuring that they remain at the forefront of combating infectious diseases in both clinical and research settings. This report provides a holistic view of where antimicrobial susceptibility testing stands in the current landscape, setting the stage for understanding its profound impact and the transformative shifts that lie ahead.

Transformative Shifts in the Testing Landscape

Recent years have witnessed a transformative evolution in the antimicrobial susceptibility testing landscape. Accelerated by the pressures of emerging infectious diseases and the increasing complexity of resistant pathogens, the sector has seen substantial changes powered by rapid technological advancements and strategic market realignments. The integration of automated systems, advanced computational tools, and streamlined workflows has redefined the methodologies of testing, reducing time delays and increasing the precision of diagnostic results.

Automatically operated platforms and digitized analysis have become the standard in many clinical and research laboratories, transitioning away from traditional manual techniques. This shift is largely attributed to enhanced capabilities of automated analyzers which offer improved reproducibility, standardization, and the ability to process large volume samples. The convergence of hardware innovations and software integration is currently driving a paradigm shift that ensures more sensitive detection of antimicrobial resistance patterns.

Furthermore, this evolution has not only impacted instrumental design and procedural approaches but also the strategic frameworks of service providers. The emerging reliance on comprehensive analytical testing and custom solutions is paving the way for more dynamic and responsive testing environments. As these changes converge, the sector benefits from a reduction in human errors, increased throughput, and a stronger capacity to tailor solutions for specific clinical challenges. Consequently, the modern landscape is defined by its adaptive nature, making it an exciting time for both seasoned experts and emerging innovators in antimicrobial susceptibility testing.

Key Segmentation Insights Driving Market Dynamics

The market for antimicrobial susceptibility testing is characterized by a complex segmentation structure that enhances its ability to address diverse needs across various applications and end users. One of the key segmentation criteria is based on product type, which provides insight into how the market is divided into Instruments, Reagents & Kits, and Services. Within this broad category, Instruments are further dissected into Automated Systems and Manual Instruments, where the Automated Systems are segmented into Automated Analyzers and Automated Plate Readers. This granular categorization enables stakeholders to closely monitor the technological progress and adoption rates of both high-end automation and more conventional manual solutions.

Another critical segmentation is based on test type; the market differentiates between Antibacterial, Antifungal, Antiparasitic, and Antiviral Susceptibility Testing. This segmentation addresses the varied clinical and research requirements, emphasizing the different pathogen profiles and therapeutic needs. The field is continuously evolving to address emerging resistance patterns that demand a nuanced approach to test methodologies.

Method segmentation further refines the market dynamics, categorizing the approach into Qualitative and Quantitative Methods. Qualitative methods, such as Agar Dilution, Automated AST, Disk Diffusion, and Genotypic Methods, offer valuable insights into the presence or absence of microbial resistance, while Quantitative methods, including Broth Macrodilution and the Etest Method, provide precise measures of susceptibility that are critical for tailoring treatment protocols. In addition, the segmentation based on application focuses on Clinical Diagnostics, Drug Discovery & Development, and Epidemiology, thereby facilitating specialized analysis of usage contexts and evolution of demand in distinct medical and research fields.

The segmentation framework is further bolstered by an end-user perspective that categorizes the market amongst Academic & Government Research Institutes, Hospitals & Diagnostic Centers, and Pharmaceutical & Biotechnology Companies. This stratification not only highlights the diverse range of entities utilizing antimicrobial susceptibility testing solutions but also points to the varied decision-making factors that drive procurement and technology adoption. Overall, these segmentation insights provide a comprehensive perspective on the multifaceted market components and their relative impact on the advancement of antimicrobial susceptibility testing technology.

Based on Product Type, market is studied across Instruments, Reagents & Kits, and Services. The Instruments is further studied across Automated Systems and Manual Instruments. The Automated Systems is further studied across Automated Analyzers and Automated Plate Readers. The Reagents & Kits is further studied across Antibiotic Susceptibility Kits and Microbial Identification Kits. The Services is further studied across Analytical Testing Services and Custom Testing Solutions.

Based on Test Type, market is studied across Antibacterial Susceptibility Testing, Antifungal Susceptibility Testing, Antiparasitic Susceptibility Testing, and Antiviral Susceptibility Testing.

Based on Method, market is studied across Qualitative Methods and Quantitative Methods. The Qualitative Methods is further studied across Agar Dilution, Automated Ast, Disk Diffusion, and Genotypic Method. The Quantitative Methods is further studied across Broth Macrodilution and Etest Method.

Based on Application, market is studied across Clinical Diagnostics, Drug Discovery & Development, and Epidemiology.

Based on End User, market is studied across Academic & Government Research Institutes, Hospitals & Diagnostic Centers, and Pharmaceutical & Biotechnology Companies.

Key Regional Insights Illuminating Global Trends

A regional analysis of the antimicrobial susceptibility testing market reveals significant variations in the adoption and innovation landscape. In the Americas, robust healthcare infrastructure, rigorous regulatory frameworks, and an increasing focus on precision medicine have fueled the integration of advanced testing protocols. Countries within this region benefit from early adoption of novel technologies, supported by high levels of investment in healthcare and research, which together drive growth in this segment.

In Europe, Middle East & Africa, the market segmentation reflects both mature and emerging economies. European nations, renowned for their stringent regulatory oversight and investment in research, continue to be at the forefront of diagnostic innovation. Meanwhile, the Middle East and Africa are progressively catching up in terms of technology adoption, with significant investments being made to upgrade laboratory infrastructure and enhance diagnostic capabilities. These regions are actively bridging gaps through collaborations between public institutions and private enterprises, setting a dynamic stage for expansion.

Across the Asia-Pacific region, rapid industrialization coupled with increasing demand for efficient healthcare solutions has underpinned the growth of antimicrobial susceptibility testing. The region is witnessing an accelerated uptake of automation and digital technologies, supported by initiatives geared towards improving healthcare accessibility and quality. Government-led initiatives and partnerships between local and international firms also contribute to a competitive landscape, marking the Asia-Pacific as a vibrant and evolving market that plays a pivotal role in shaping global trends in antimicrobial testing.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping the Market Landscape

The competitive arena is marked by a confluence of established market players and innovative newcomers, each contributing to the advancement of antimicrobial susceptibility testing. Prominent companies such as Accelerate Diagnostics, Inc., Alifax S.r.l., and Becton, Dickinson and Company help drive technological innovation through their pioneering instruments and comprehensive testing solutions. Leading entities like Bio-Rad Laboratories, Inc., BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti., and Biological Safety Solutions Ltd/Oy serve critical roles in the segmentation of reagents and kits, constantly pushing the boundaries of test efficiency and accuracy.

Market leaders including BioMerieux SA and Bruker Corporation are continuously expanding their portfolios, integrating new methodologies and digital analytics to increase the robustness of test outcomes. Creative Diagnostics and Danaher Corporation, along with Erba Lachema s.r.o., fortify this competitive landscape by providing state-of-the-art custom testing services and analytical solutions that adapt to the changing needs of clinical diagnostics.

Eurofins Scientific SE and F. Hoffmann-La Roche AG further underscore the importance of quality and performance in diagnostic methods, while companies such as Himedia Laboratories Private Limited and INTEGRA Biosciences AG ensure that testing remains accessible and technically sound. Laboratorios Conda, S.A., Launch Diagnostics Limited, and Leading Biology, Inc. deliver specialized testing kits and instruments that meet rigorous demands across both clinical and research applications. In addition, Liofilchem S.r.l., Mast Group Ltd., MP Biomedicals, LLC, and Pfizer Inc. are known for their contributions to both the development of test protocols and the refinement of instrument technology.

Moreover, Qiagen N.V., QuantaMatrix Inc., Resistell AG, Synoptics Group, Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd. together represent the spectrum of global innovation that drives the market forward. Their diverse strategies, ranging from groundbreaking research and development to agile market adaptations, collectively shape an ecosystem that seeks to offer faster, more accurate, and cost-effective antimicrobial susceptibility testing solutions. This mosaic of market players ensures that the industry remains dynamic and responsive to both clinical and research challenges.

The report delves into recent significant developments in the Antimicrobial Susceptibility Testing Market, highlighting leading vendors and their innovative profiles. These include Accelerate Diagnostics, Inc., Alifax S.r.l., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti., Biological Safety Solutions Ltd/Oy, BioMerieux SA, Bruker Corporation, Creative Diagnostics, Danaher Corporation, Erba Lachema s.r.o., Eurofins Scientific SE, F. Hoffmann-La Roche AG, Himedia Laboratories Private Limited, INTEGRA Biosciences AG, Laboratorios Conda, S.A., Launch Diagnostics Limited, Leading Biology, Inc., Liofilchem S.r.l., Mast Group Ltd., MP Biomedicals, LLC, Pfizer Inc., Qiagen N.V., QuantaMatrix Inc., Resistell AG, Synoptics Group, Thermo Fisher Scientific Inc., and Zhuhai DL Biotech Co., Ltd.. Actionable Recommendations for Industry Leaders

For industry leaders navigating the complex realm of antimicrobial susceptibility testing, it is crucial to adopt a forward-thinking approach built on strategic investments and collaborative engagements. Embracing automation and digital integration should be a top priority. Leaders are encouraged to invest in state-of-the-art automated laboratory systems and digital diagnostic tools that not only boost efficiency but also enhance accuracy in test results. Leveraging data analytics can provide deeper insights into microbial resistance trends, facilitating more targeted research and effective clinical interventions.

Developing strong partnerships with technology innovators and research institutions is another key strategy. Collaborative efforts can unlock access to next-generation diagnostics, enabling companies to remain competitive in a rapidly evolving market. In tandem, establishing a robust global supply chain is vital to ensure that high-quality testing materials and instruments are readily available even amidst fluctuations in demand or disruptions in production.

Furthermore, it is essential for decision-makers to diversify their product portfolios. By incorporating a balanced range of qualitative and quantitative methods, industry leaders can cater to a wider array of diagnostic requirements. Companies should also consider targeted investments in customizable testing solutions that can cater to the evolving demands of clinical diagnostics, drug development, and epidemiological studies.

From a regulatory standpoint, proactive engagement with policy makers and adherence to evolving quality standards can reinforce market presence. Leaders must prioritize compliance while simultaneously advocating for innovation-friendly policies that expedite the adoption of breakthrough diagnostic technologies. Lastly, continuous professional development and training for laboratory personnel is crucial to maintain operational excellence and ensure that teams are well-versed in the latest methodologies and technological advancements.

Taking a holistic, multifaceted approach that blends technology, strategic partnerships, and regulatory foresight will be instrumental for industry leaders seeking to drive forward the advancement of antimicrobial susceptibility testing.

Conclusion: Charting the Future of Diagnostic Excellence

The journey through the dynamic landscape of antimicrobial susceptibility testing highlights a sector that is in the midst of revolutionary change. With a clear convergence of innovative technologies, transformative market shifts, and highly diverse segmentation patterns, the industry is poised for sustained growth and enhanced diagnostic precision. The insights provided reveal that the specialized categorization based on product types, test methods, and application areas not only enables a more refined analysis of the market but also underscores the need for tailored solutions in the fight against antimicrobial resistance.

Regional diversity further accentuates the global impact, with varied adoption rates and infrastructural developments influencing market trajectories. The Americas lead with a robust infrastructure and early adoption of cutting-edge technologies, while Europe, Middle East & Africa and Asia-Pacific display unique competitive dynamics that contribute to an integrated global market landscape. These regional insights provide direction for strategic investments, underlining the critical role of adaptive policies and international collaborations in advancing diagnostic capabilities.

The collective efforts of prominent industry players are equally instrumental in shaping market trends. The synergy of technological innovation, comprehensive service portfolios, and strong market presence among leading companies underscores a commitment to quality and progress. The sector appears well-equipped to meet future challenges, driving forward initiatives that blend research, technological innovation, and agile market responses.

In summary, the findings highlighted herein affirm that the antimicrobial susceptibility testing market is not only sustainable but continues to evolve at an impressive pace. With transformative technologies and collaborative strategies at the helm, decision-makers are well-positioned to spearhead advancements that will further enhance diagnostic efficiency and accuracy. This promising outlook is underpinned by a commitment to continuous innovation and an adaptive approach to market needs, setting the stage for a future defined by diagnostic excellence and improved global health outcomes.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Importance of antimicrobial susceptibility testing in medical decision-making
    • 5.1.1.2. Favorable government initiatives aiming to combat and prevent infectious diseases
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of antimicrobial susceptibility kits and lack of skilled professionals
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of new genomic identification methods and launch of antimicrobial susceptibility test kits
    • 5.1.3.2. Ongoing research on nanoparticles-based antimicrobial susceptibility
  • 5.1.4. Challenges
    • 5.1.4.1. Incidence of product recalls and strict regulations regarding antimicrobial susceptibility testing commercialization
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product Type: Growing demand for antimicrobial susceptibility testing owing to precision and efficiency,
  • 5.2.2. Test Type: Significant advancements in antifungal susceptibility testing due to heightened awareness of invasive fungal infections
  • 5.2.3. Method: Development of qualitative AST techniques with increased accuracy of the tests
  • 5.2.4. Application: Rapid and extreme utilization of the AST in clinical diagnostics and drug discovery and development
  • 5.2.5. End User: Extensive use of AST in hospitals and diagnostic laboratories
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Antimicrobial Susceptibility Testing Market, by Product Type

• 6.1. Introduction
• 6.2. Instruments
  • 6.2.1. Automated Systems
    • 6.2.1.1. Automated Analyzers
    • 6.2.1.2. Automated Plate Readers
  • 6.2.2. Manual Instruments
• 6.3. Reagents & Kits
  • 6.3.1. Antibiotic Susceptibility Kits
  • 6.3.2. Microbial Identification Kits
• 6.4. Services
  • 6.4.1. Analytical Testing Services
  • 6.4.2. Custom Testing Solutions

7. Antimicrobial Susceptibility Testing Market, by Test Type

• 7.1. Introduction
• 7.2. Antibacterial Susceptibility Testing
• 7.3. Antifungal Susceptibility Testing
• 7.4. Antiparasitic Susceptibility Testing
• 7.5. Antiviral Susceptibility Testing

8. Antimicrobial Susceptibility Testing Market, by Method

• 8.1. Introduction
• 8.2. Qualitative Methods
  • 8.2.1. Agar Dilution
  • 8.2.2. Automated Ast
  • 8.2.3. Disk Diffusion
  • 8.2.4. Genotypic Method
• 8.3. Quantitative Methods
  • 8.3.1. Broth Macrodilution
  • 8.3.2. Etest Method

9. Antimicrobial Susceptibility Testing Market, by Application

• 9.1. Introduction
• 9.2. Clinical Diagnostics
• 9.3. Drug Discovery & Development
• 9.4. Epidemiology

10. Antimicrobial Susceptibility Testing Market, by End User

• 10.1. Introduction
• 10.2. Academic & Government Research Institutes
• 10.3. Hospitals & Diagnostic Centers
• 10.4. Pharmaceutical & Biotechnology Companies

11. Americas Antimicrobial Susceptibility Testing Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Antimicrobial Susceptibility Testing Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Antimicrobial Susceptibility Testing Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
  • 14.3.1. iFAST Diagnostics secures USD 6.5 million investment to enhance rapid antimicrobial susceptibility testing
  • 14.3.2. VITEK REVEAL GN AST assay developed from BARDA gains FDA clearance to revolutionize antimicrobial testing
  • 14.3.3. QuantaMatrix launches fastest antimicrobial testing with 'uRAST'
  • 14.3.4. Wockhardt to launch groundbreaking antibiotic Zaynich, targeting global multi-drug resistant superbugs
  • 14.3.5. CARB-X awards USD 1 million to Prompt Diagnostics to advance rapid PCR testing for resistant gonorrhea
  • 14.3.6. bioMerieux gains FDA clearance for VITEK REVEAL AST system
  • 14.3.7. Malawi Ministry of Health, bioMerieux, and Pfizer join forces to combat antimicrobial resistance
  • 14.3.8. BARDA announces FDA clearance of PBC separator with Selux AST System
  • 14.3.9. FDA clears avails medical's eQUANT system for enhanced antibiotic testing
  • 14.3.10. Shionogi launches fetroja to combat drug-resistant infections and expand global access
  • 14.3.11. Day Zero Diagnostics unveils AI-powered antimicrobial susceptibility testing advances at IDWeek 2023
  • 14.3.12. Strathclyde spin-out Microplate dx secures GBP 2.5 million in funding
  • 14.3.13. Sysmex unveils rapid antimicrobial susceptibility testing system in Europe addressing AMR challenges
• 14.4. Strategy Analysis & Recommendation
  • 14.4.1. Thermo Fisher Scientific Inc.
  • 14.4.2. BioMerieux SA
  • 14.4.3. QuantaMatrix Inc.
  • 14.4.4. Bio-Rad Laboratories, Inc.

Companies Mentioned

• 1. Accelerate Diagnostics, Inc.
• 2. Alifax S.r.l.
• 3. Becton, Dickinson and Company
• 4. Bio-Rad Laboratories, Inc.
• 5. BIOANALYSE TIbbi Malz. San. ve Tic. Ltd. Sti.
• 6. Biological Safety Solutions Ltd/Oy
• 7. BioMerieux SA
• 8. Bruker Corporation
• 9. Creative Diagnostics
• 10. Danaher Corporation
• 11. Erba Lachema s.r.o.
• 12. Eurofins Scientific SE
• 13. F. Hoffmann-La Roche AG
• 14. Himedia Laboratories Private Limited
• 15. INTEGRA Biosciences AG
• 16. Laboratorios Conda, S.A.
• 17. Launch Diagnostics Limited
• 18. Leading Biology, Inc.
• 19. Liofilchem S.r.l.
• 20. Mast Group Ltd.
• 21. MP Biomedicals, LLC
• 22. Pfizer Inc.
• 23. Qiagen N.V.
• 24. QuantaMatrix Inc.
• 25. Resistell AG
• 26. Synoptics Group
• 27. Thermo Fisher Scientific Inc.
• 28. Zhuhai DL Biotech Co., Ltd.